Written by the AllMyPeptides Research Team
Tesamorelin vs CJC-1295: At a Glance
Both Tesamorelin and CJC-1295 are GHRH analogues studied for their action on the growth-hormone axis. Tesamorelin is the full GHRH(1–44) sequence with a stabilising modification and exists as an approved medicine for a narrow indication; CJC-1295 is a shorter GHRH analogue used as a research compound.
Research use only. Both compounds are supplied for in-vitro laboratory research. Neither is a medicine, and neither is for human or veterinary consumption, administration, or therapeutic use.
How They Differ — Structure & Half-Life
Tesamorelin carries a trans-3-hexenoic acid modification on the full GHRH sequence and has a short half-life producing a discrete GH pulse. CJC-1295 (commonly the "No-DAC"/Mod GRF 1-29 form) is a modified shorter GHRH fragment studied for GH-releasing activity. Both ultimately act at the GHRH receptor but differ in sequence and pharmacokinetics.
Evidence & Regulatory Status
Tesamorelin is FDA-approved in the US for HIV-associated lipodystrophy but unlicensed in the UK; CJC-1295 is a research compound with no approval. Research-grade material of either is supplied for laboratory use only. For a related GH-axis comparison see CJC-1295 vs Ipamorelin.
Sourcing for Research
Verify any GHRH analogue against a batch-matched COA. View Tesamorelin and CJC-1295 product details.
Frequently Asked Questions
What is the difference between Tesamorelin and CJC-1295?+
Are Tesamorelin or CJC-1295 approved in the UK?+
Do they work the same way?+
Related Guides
Products discussed in this guide are for research and laboratory use only. AllMyPeptides does not condone or support misuse of any research materials. Not for human or animal consumption.